KR20240023267A - Anti-inflammatory composition containing plum juice as an active ingredient - Google Patents
Anti-inflammatory composition containing plum juice as an active ingredient Download PDFInfo
- Publication number
- KR20240023267A KR20240023267A KR1020220100612A KR20220100612A KR20240023267A KR 20240023267 A KR20240023267 A KR 20240023267A KR 1020220100612 A KR1020220100612 A KR 1020220100612A KR 20220100612 A KR20220100612 A KR 20220100612A KR 20240023267 A KR20240023267 A KR 20240023267A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- inflammatory
- inflammatory diseases
- plum juice
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 30
- 235000011389 fruit/vegetable juice Nutrition 0.000 title claims abstract description 20
- 239000004480 active ingredient Substances 0.000 title claims abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 47
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims abstract description 12
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 11
- 240000007472 Leucaena leucocephala Species 0.000 claims abstract description 9
- 235000020230 cinnamon extract Nutrition 0.000 claims abstract description 9
- 235000019537 butterbur extract Nutrition 0.000 claims abstract description 8
- 235000005340 Asparagus officinalis Nutrition 0.000 claims abstract description 7
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 5
- 206010009887 colitis Diseases 0.000 claims abstract description 5
- 201000003146 cystitis Diseases 0.000 claims abstract description 5
- 208000006454 hepatitis Diseases 0.000 claims abstract description 5
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 5
- 201000008383 nephritis Diseases 0.000 claims abstract description 5
- 244000003416 Asparagus officinalis Species 0.000 claims abstract 2
- 240000002834 Paulownia tomentosa Species 0.000 claims abstract 2
- 235000000346 sugar Nutrition 0.000 claims description 21
- 235000021018 plums Nutrition 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 206010030113 Oedema Diseases 0.000 claims description 4
- 206010010741 Conjunctivitis Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 201000002481 Myositis Diseases 0.000 claims description 3
- 206010033078 Otitis media Diseases 0.000 claims description 3
- 206010034464 Periarthritis Diseases 0.000 claims description 3
- 201000007100 Pharyngitis Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 201000002661 Spondylitis Diseases 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 208000000491 Tendinopathy Diseases 0.000 claims description 3
- 206010043255 Tendonitis Diseases 0.000 claims description 3
- 208000004760 Tenosynovitis Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 201000005917 gastric ulcer Diseases 0.000 claims description 3
- 208000014617 hemorrhoid Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 201000001245 periodontitis Diseases 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 201000003068 rheumatic fever Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 201000004415 tendinitis Diseases 0.000 claims description 3
- 206010044008 tonsillitis Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 230000002757 inflammatory effect Effects 0.000 abstract description 3
- 206010003246 arthritis Diseases 0.000 abstract description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 22
- 239000002158 endotoxin Substances 0.000 description 13
- 229920006008 lipopolysaccharide Polymers 0.000 description 13
- 244000055346 Paulownia Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000000605 extraction Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 244000193174 agave Species 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 102000003945 NF-kappa B Human genes 0.000 description 5
- 108010057466 NF-kappa B Proteins 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 235000017803 cinnamon Nutrition 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 241000220479 Acacia Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 3
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 2
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000004676 glycans Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 2
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- -1 olive oil Chemical compound 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- ZCUQOPGIJRGJDA-UHFFFAOYSA-N 1-naphthalen-1-ylethane-1,2-diamine Chemical compound C1=CC=C2C(C(N)CN)=CC=CC2=C1 ZCUQOPGIJRGJDA-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000006595 Griess deamination reaction Methods 0.000 description 1
- 102100031153 Growth arrest and DNA damage-inducible protein GADD45 beta Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001066164 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 beta Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 description 1
- 101710199010 Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 240000003296 Petasites japonicus Species 0.000 description 1
- 235000003823 Petasites japonicus Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000011229 Prunus domestica subsp. syriaca Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000169641 Spondias dulcis Species 0.000 description 1
- 235000005138 Spondias dulcis Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 240000000377 Tussilago farfara Species 0.000 description 1
- 235000004869 Tussilago farfara Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000001436 butterbur Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007934 lip balm Substances 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000003817 vacuum liquid chromatography Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 매실 착즙액을 유효성분으로 함유하는 항염용 조성물에 관한 것에 관한 것으로서, 상기 사료 조성물은 벽오동 추출물, 아까시 추출물, 머위 추출물, 계피 추출물 및 아스파라거스 추출물이 더 추가됨으로써 인체에 무해하면서도 각종 염증 증상을 억제하는 효능이 우수하여, 대장염, 관절염, 간염, 방광염, 신장염, 피부염 등과 같은 다양한 염증질환의 치료제, 증상 개선용 식품, 화장료 등으로 사용가능하다. The present invention relates to an anti-inflammatory composition containing plum juice as an active ingredient. The feed composition is harmless to the human body and causes various inflammatory symptoms by further adding paulownia extract, acacia extract, butterbur extract, cinnamon extract, and asparagus extract. It has excellent efficacy in suppressing , and can be used as a treatment for various inflammatory diseases such as colitis, arthritis, hepatitis, cystitis, nephritis, dermatitis, etc., food for improving symptoms, and cosmetics.
Description
본 발명은 매실 착즙액을 유효성분으로 함유하는 항염용 조성물에 관한 것이다. The present invention relates to an anti-inflammatory composition containing plum juice as an active ingredient.
염증반응이 일어나는 기작은 대식세포(macrophage)가 병원체에 반응하여 TNF-α(tumor necrotic factor-α), IL-6(interleukin-6), 및 IL-1β와 같은 염증유발인자(pro-inflammatory cytokine)을 생성하고, iNOS(inducible nitric oxide synthase)와 COX-2(cyclooxygenase-2)를 합성하여 일산화질소(NO) 및 PGE2(prostaglandin E2)를 생성한다. 생리학적으로 NO는 세균과 종양을 제거하고 혈압을 조절하거나 신경 전달을 매개하는 등 다양한 역할을 수행한다. 그러나 염증 반응이 일어나면 관련 세포에서 iNOS의 발현이 증가하여 많은 양의 NO 생성하고, 과도하게 생성된 NO는 조직의 손상, 유전자 변이, 신경 손상 등을 유발하며, 혈관투과성을 증가시켜 부종 등의 염증 반응을 촉진시킨다. PGE2는 통증과 발열에 주로 관여하는 염증 인자로서 염증반응이 일어나면 대식세포의 COX-2에 의해 생성된다. 그러므로, 염증 반응에서 생성되는 물질 중 NO 및 PGE2와 같은 물질의 생성 억제를 확인하여 항염증 효과를 확인할 수 있다.The mechanism by which the inflammatory response occurs is when macrophages react to pathogens and produce pro-inflammatory cytokines such as tumor necrotic factor-α (TNF-α), interleukin-6 (IL-6), and IL-1β. ), and synthesizes iNOS (inducible nitric oxide synthase) and COX-2 (cyclooxygenase-2) to produce nitric oxide (NO) and PGE2 (prostaglandin E2). Physiologically, NO plays a variety of roles, including eliminating bacteria and tumors, regulating blood pressure, and mediating nerve transmission. However, when an inflammatory reaction occurs, the expression of iNOS increases in related cells, producing a large amount of NO. Excessively produced NO causes tissue damage, genetic mutation, and nerve damage, and increases vascular permeability, causing inflammation such as edema. Accelerates the reaction. PGE2 is an inflammatory factor mainly involved in pain and fever and is produced by COX-2 of macrophages when an inflammatory response occurs. Therefore, the anti-inflammatory effect can be confirmed by checking the inhibition of production of substances such as NO and PGE2 among substances produced in the inflammatory response.
한편, LPS에 의한 대식세포의 활성화 과정은 TLR(toll-like receptor)에 의해 매개되며 전사 인자(transcription factor)인 NF-κB(nuclear factor-κB)을 활성화시키는 경로를 통해 이루어진다. LPS는 그람 음성 (-)균의 세포 외벽에 존재하며 핵 부위(core region)과 O-다당류 부위(polysaccharide region)으로 이루어진 다당류 부위(polysaccharide region)과 지질(lipid) A로 알려진 지질 부위(lipid region)로 구성되어 있다. LPS의 지질 A가 그람 음성균의 병태생리학에 있어서 중요한 역할을 하는 것으로 알려져 있다. LPS의 지질 A에 의해 대식세포 표면에 있는 TLR-4가 자극되면 세포질 내의 Toll/IL-1R(TIR) 도메인으로 신호가 전달된다. 이렇게 대식세포 내로 전달된 신호는 MyD88(myeloid differentiation primary-response protein 88)와 연결을 유도하고 IRAK4(IL-1R-associated kinase 4)를 신호 전달 경로로 유도한다. 이 IRAK-4는 IRAK1을 인산화하여 TRAF6(tumour-necrosis-factor-receptor-associated factor 6)도 신호 전달 체계로 합류된다. 인산화된 IRAK1과 TRAF6는 신호수용체(receptor complex)에서 분리되어 세포막에서 다른 기전을 거쳐 다시 세포질에서 TAK1(transforming-growth-factor-β-activated kinase)을 활성화시킨다. 활성화된 TAK1은 MAP(mitogen-activated protein) 키나아제와 IKK(inhibitor of nuclear factor-κB (IκB)-kinasecomplex) 복합체를 인산화시켜 IκB와 NF-κB 분해를 유도한다. 분리된 NF-κB는 대식세포의 핵으로 이동하여 염증과 관련된 유전자의 발현을 유도하여 여러 사이토카인과 단백질을 생성한다.Meanwhile, the activation process of macrophages by LPS is mediated by TLR (toll-like receptor) and occurs through a pathway that activates NF-κB (nuclear factor-κB), a transcription factor. LPS is present in the outer cell wall of Gram-negative (-) bacteria and has a polysaccharide region consisting of a core region and an O-polysaccharide region and a lipid region known as lipid A. ) is composed of. Lipid A of LPS is known to play an important role in the pathophysiology of Gram-negative bacteria. When TLR-4 on the surface of macrophages is stimulated by lipid A of LPS, a signal is transmitted to the Toll/IL-1R (TIR) domain in the cytoplasm. The signal transmitted into macrophages in this way induces connection with MyD88 (myeloid differentiation primary-response protein 88) and induces IRAK4 (IL-1R-associated kinase 4) into the signal transduction pathway. This IRAK-4 phosphorylates IRAK1, and TRAF6 (tumour-necrosis-factor-receptor-associated factor 6) also joins the signal transduction system. Phosphorylated IRAK1 and TRAF6 are separated from the signal receptor complex and go through a different mechanism in the cell membrane to activate TAK1 (transforming-growth-factor-β-activated kinase) in the cytoplasm. Activated TAK1 phosphorylates MAP (mitogen-activated protein) kinase and IKK (inhibitor of nuclear factor-κB (IκB)-kinasecomplex) complex, leading to IκB and NF-κB degradation. The isolated NF-κB moves to the nucleus of macrophages and induces the expression of genes related to inflammation, producing several cytokines and proteins.
매실은 식중독, 전염병 등의 예방 및 치료를 목적으로 예전부터 사용되어 오던 물질이다. 현재도 식품의 보전 등의 목적으로 많이 연구되고 있으며, 특히 구연산, 사과산 등이 많이 함유되어 있어 이를 통한 살균력은 널리 알려져 있다. Plum is a substance that has long been used for the purpose of preventing and treating food poisoning and infectious diseases. Currently, it is being studied extensively for purposes such as food preservation. In particular, it contains a lot of citric acid and malic acid, so its sterilizing power is widely known.
본 발명자들은 이러한 매실을 이용하여 항염 관련 조성물에 관한 다양한 연구를 수행하던 중, 상기 매실 착즙액이 LPS로 활성화된 대식세포에서 NO의 생성을 억제하는 것을 확인하여 본 발명을 완성하게 되었다. While conducting various studies on anti-inflammatory compositions using plums, the present inventors confirmed that the plum juice inhibits the production of NO in macrophages activated by LPS, thereby completing the present invention.
본 발명의 목적은 매실 착즙액을 유효성분으로 함유하는 항염용 조성물을 제공하는 데에 있다. The purpose of the present invention is to provide an anti-inflammatory composition containing plum juice as an active ingredient.
본 발명은 매실 착즙액, 벽오동 추출물, 아까시 추출물, 머위 추출물, 계피 추출물 및 아스파라거스 추출물이 함유된 것을 특징으로 하는 항염용 조성물에 관한 것이다. The present invention relates to an anti-inflammatory composition containing plum juice, paulownia extract, acacia extract, butterbur extract, cinnamon extract, and asparagus extract.
상기 항염용 조성물은 매실 착즙액 100 중량부 기준으로 벽오동 추출물 20~30 중량부, 아까시 추출물 5~14 중량부, 머위 추출물 20~30 중량부, 계피 추출물 3~15 중량부 및 아스파라거스 추출물 10~20 중량부가 함유된 것일 수 있다. The anti-inflammatory composition contains 20 to 30 parts by weight of paulownia extract, 5 to 14 parts by weight of acacia extract, 20 to 30 parts by weight of butterbur extract, 3 to 15 parts by weight of cinnamon extract, and 10 to 20 parts by weight of asparagus extract, based on 100 parts by weight of plum juice. It may contain parts by weight.
상기 항염용 조성물에는 매실 당 추출물이 함유될 수 있다. 상기 매실 당 추출물은 매실 착즙액 100 중량부 기준으로 10~30 중량부가 혼합될 수 있다. The anti-inflammatory composition may contain plum sugar extract. The plum sugar extract may be mixed in an amount of 10 to 30 parts by weight based on 100 parts by weight of plum juice.
상기 각 추출물은 각 원료 시료를 준비하고, 상기 원료 시료를 물, C1~C4 알코올 또는 이들의 혼합용액을 용매로 하여 추출할 수 있다. 상기 용매로는 바람직하게 물을 사용하는 것이 가장 좋다. Each of the extracts may be prepared by preparing each raw material sample and extracting the raw material sample using water, C1 to C4 alcohol, or a mixed solution thereof as a solvent. It is best to use water as the solvent.
이하, 본 발명을 상세하게 설명한다. Hereinafter, the present invention will be described in detail.
본 발명에서 사용하는 매실 착즙액은 생매실을 분쇄하고 압착(착즙) 후 수득한 액상을 가열하여 얻은 것을 특징으로 하며, 황매실 또는 청매실을 사용할 수 있다. 또한 생매실을 분쇄하고 압착하여 착즙함으로써 수득한 액상을 1차 가열하고, 원심분리하고 마이크로필터로 필터링한 후 다시 2차 가열한 것을 사용할 수 있다. 원심분리는 4~10℃, 8000~10000rpm에서 5~30분 동안 수행하는 것이 바람직하며, 70~125℃에서 0.5~48시간 동안 1차 또는 2차 가열할 수 있다. 마이크로필터는 기공크기 0.2~0.45μm인 것을 사용할 수 있다. The plum juice used in the present invention is obtained by crushing raw plums and heating the liquid obtained after pressing (juicing), and yellow plums or green plums can be used. In addition, the liquid obtained by crushing, pressing, and extracting fresh plums can be used by first heating, centrifuging, filtering with a microfilter, and then heating again a second time. Centrifugation is preferably performed at 4 to 10°C and 8000 to 10000 rpm for 5 to 30 minutes, and primary or secondary heating can be performed at 70 to 125°C for 0.5 to 48 hours. Microfilters can be used with pore sizes of 0.2 to 0.45 μm.
본 발명의 조성물에는 매실 당 추출물이 더 첨가될 수 있다. 본 발명에서 사용하는 매실 당 추출물은 매실에 당류를 혼합한 혼합물을 그대로 두어 삼투 추출한 것에서 건더기를 제거한 액상일 수 있다. 상기 매실 당 추출물은 매실 100 중량부 기준으로 당류 50~200 중량부를 혼합한 혼합물을 3~6개월 동안 그대로 두어 삼투 추출한 것에서 건더기를 제거한 액상일 수 있다. 상기 매실 당 추출물의 추출 온도는 4~37℃인 것이 좋고, 바람직하게는 15~30℃인 것이 더 좋다. 상기 당류는 단맛을 내는 것은 어떠한 것이라도 사용가능하나 설탕, 슈가파우더, 올리고당, 아가베시럽, 메이플시럽, 선인장설탕 및 꿀로 이루어진 군에서 선택되는 1종 이상의 것을 사용할 수 있다. 이 때, 매실 100 중량부 기준으로 당류가 50 중량부 미만으로 혼합되면 발효가 되지 않고 부패가 되기 쉽다. 또한, 매실 100 중량부 기준으로 당류가 200 중량부를 초과하여 혼합되면 당류 성분의 과첨가로 인해 당류와 매실로부터 추출되는 즙이 혼합되지 않을 수 있다. 또한, 추출기간이 3개월 미만이면 이후 부패가 되기 쉽고, 추출기간이 6개월을 초과하게 되면, 초산발효나 알코올 발효가 진행될 수도 있으며, 보관장소나 환경에 따라서 부패가 진행될 수도 있다. Plum sugar extract may be further added to the composition of the present invention. The plum sugar extract used in the present invention may be a liquid obtained by removing the dry matter from a mixture of plums and sugars obtained by osmosis extraction. The plum sugar extract may be a liquid obtained by removing the dry matter from a mixture of 50 to 200 parts by weight of sugars based on 100 parts by weight of plums, which is extracted by osmosis by leaving it as is for 3 to 6 months. The extraction temperature of the plum sugar extract is preferably 4 to 37°C, and more preferably 15 to 30°C. Any sweetener can be used as the sugar, but at least one selected from the group consisting of sugar, sugar powder, oligosaccharide, agave syrup, maple syrup, cactus sugar, and honey can be used. At this time, if sugars are mixed in an amount of less than 50 parts by weight based on 100 parts by weight of plums, fermentation does not occur and it is easy to spoil. In addition, if more than 200 parts by weight of sugars are mixed based on 100 parts by weight of plums, the sugars and the juice extracted from the plums may not be mixed due to excessive addition of the sugar component. In addition, if the extraction period is less than 3 months, it is prone to spoilage, and if the extraction period exceeds 6 months, acetic acid fermentation or alcohol fermentation may occur, and spoilage may progress depending on the storage location or environment.
본 발명에서 사용하는 벽오동으로는 가지, 열매 및 잎에서 선택되는 1종 이상이 함유될 수 있으며, 아까시(아카시아)로는 목질부가 사용가능하다. The wall paulownia used in the present invention may contain one or more types selected from branches, fruits, and leaves, and the woody part of acacia can be used.
상기 항염용 조성물에 각 용매 추출물은 동결건조 후 매실 착즙액과 혼합될 수 있으나 추출물을 물로 추출하였을 경우, 매실 착즙액에 바로 혼합해도 무방하다. 바람직하게는 용매 추출물은 원료 시료 대비 5~20 중량부의 물을 첨가한 후 70~90℃에서 1~10시간 동안 가온하여 추출한 후 건더기를 제거하여 낸 액상인 것일 수 있다. Each solvent extract in the anti-inflammatory composition can be freeze-dried and then mixed with plum juice. However, if the extract is extracted with water, it may be mixed directly with plum juice. Preferably, the solvent extract may be a liquid obtained by adding 5 to 20 parts by weight of water compared to the raw material sample, extracting it by heating at 70 to 90 ° C. for 1 to 10 hours, and then removing the dry matter.
본 발명에서 이용하는 용매 추출물로서, 벽오동 추출물, 아까시 추출물, 머위 추출물, 계피 추출물, 아스파라거스 추출물은 다음의 방법으로 제조할 수 있다. 이를 위해 각 원료 시료를 준비하고, 상기 원료 시료를 물, C1~C4 알코올 또는 이들의 혼합용액을 용매로 하여 추출할 수 있으며, 상기 C1~C4 알코올은 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올 및 이소부탄올로 이루어진 군에서 선택될 수 있다. As solvent extracts used in the present invention, paulownia extract, acacia extract, butterbur extract, cinnamon extract, and asparagus extract can be prepared by the following method. For this purpose, each raw material sample can be prepared, and the raw material sample can be extracted using water, C1 to C4 alcohol, or a mixed solution thereof as a solvent, and the C1 to C4 alcohol is methanol, ethanol, propanol, isopropanol, butanol, and isopropanol. It may be selected from the group consisting of butanol.
상기 원료 시료의 추출조건은 20~100℃에서 1분~48시간일 수 있다. 상기 과정은 1~4번까지 반복할 수 있다. 이 때 사용하는 추출용 기기로는 통상의 추출기기, 초음파분쇄추출기 또는 분획기를 이용할 수 있다. 이렇게 제조된 용매 추출물은 열풍건조, 감압건조 또는 동결건조하여 용매를 제거할 수 있다. 또한, 상기 용매 추출물은 컬럼크로마토그래피를 이용하여 정제하여 사용할 수 있다. 상기 용매 추출물은 상법에 따라, 유기용매(알코올, 에테르, 아세톤 등)에 의한 추출, 헥산과 물의 분배, 컬럼크로마토그래피에 의한 방법 등, 식물체 성분의 분리 추출에 이용되는 공지의 방법을 단독 또는 적합하게 조합한 방법을 이용하여 분획 또는 정제하여 사용할 수 있다. 상기 크로마토그래피는 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 엘에이취-20 컬럼 크로마토그래피(LH-20 column chromatography), 이온교환수지 크로마토그래피(ion exchange resin chromatography), 중압 액체 크로마토그래피(medium pressure liquid chromatography), 박층 크로마토그래피(TLC; thin layer chromatography), 실리카겔 진공 액체 크로마토그래피(silica gel vacuum liquid chromatography) 및 고성능 액체 크로마토그래피(high performance liquid chromatography) 중에서 선택될 수 있다. Extraction conditions for the raw material sample may be 1 minute to 48 hours at 20 to 100°C. The above process can be repeated 1 to 4 times. The extraction equipment used at this time can be a regular extraction equipment, an ultrasonic grinding extractor, or a fractionator. The solvent extract prepared in this way can be dried with hot air, dried under reduced pressure, or freeze-dried to remove the solvent. Additionally, the solvent extract can be purified and used using column chromatography. The solvent extract can be extracted alone or using known methods used for separation and extraction of plant components, such as extraction with organic solvents (alcohol, ether, acetone, etc.), distribution of hexane and water, and column chromatography, according to conventional methods. It can be used after fractionation or purification using a combination of methods. The chromatography includes silica gel column chromatography, LH-20 column chromatography, ion exchange resin chromatography, and medium pressure liquid chromatography. chromatography), thin layer chromatography (TLC), silica gel vacuum liquid chromatography, and high performance liquid chromatography.
본 발명은 상기 항염용 조성물을 포함하는 염증 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases comprising the anti-inflammatory composition.
상기 염증 질환은 아토피 피부염, 부종, 피부염, 알레르기, 천식, 결막염, 치주염, 비염, 중이염, 인후염, 편도염, 폐렴, 위궤양, 위염, 크론병, 대장염, 치질, 통풍, 간직성 척추염, 류마티스 열루푸스, 섬유근통(fibromyalgia), 건선관절염, 골관절염, 류마티스관절염, 견관절주위염, 건염, 건초염, 근육염, 간염, 방광염, 신장염, 쇼그렌 증후군(sjogren's syndrome) 및 다발성 경화증으로 이루어지는 군으로부터 선택되는 것일 수 있다. The inflammatory diseases include atopic dermatitis, edema, dermatitis, allergy, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, pharyngitis, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, mesenteric spondylitis, rheumatic fever, It may be selected from the group consisting of fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendonitis, tenosynovitis, myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome and multiple sclerosis.
상기 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 상기 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 항염용 조성물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 탄산칼슘, 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. The pharmaceutical composition can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions according to conventional methods. Carriers, excipients, and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, and cellulose. , methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations contain at least one excipient, such as starch, calcium carbonate, sucrose, or It is prepared by mixing lactose and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, oral solutions, emulsions, syrups, etc. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. . Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao, laurin, glycerogeratin, etc. can be used.
본 발명의 약학 조성물의 투여량은 치료받을 대상의 연령, 성별, 체중과, 치료할 특정 질환 또는 병리 상태, 질환 또는 병리 상태의 심각도, 투여경로 및 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있으며, 일반적으로 투여량은 0.01㎎/㎏/일 내지 대략 2000㎎/㎏/일의 범위이다. 더 바람직한 투여량은 1㎎/㎏/일 내지 500㎎/㎏/일이다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. The dosage of the pharmaceutical composition of the present invention will vary depending on the age, gender, and weight of the subject to be treated, the specific disease or pathological state to be treated, the severity of the disease or pathological state, the route of administration, and the judgment of the prescriber. Dosage determinations based on these factors are within the level of one skilled in the art, and dosages generally range from 0.01 mg/kg/day to approximately 2000 mg/kg/day. A more preferred dosage is 1 mg/kg/day to 500 mg/kg/day. Administration may be administered once a day, or may be administered several times. The above dosage does not limit the scope of the present invention in any way.
본 발명의 약학 조성물은 쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 주사에 의해 투여될 수 있다. The pharmaceutical composition of the present invention can be administered to mammals such as rats, livestock, and humans through various routes. All modes of administration are contemplated, for example, oral, rectal or by intravenous, intramuscular, subcutaneous, intrathecal or intracerebrovascular injection.
본 발명은 상기 항염용 조성물을 포함하는 염증 질환의 예방 또는 개선용 건강기능식품을 제공한다. The present invention provides a health functional food for preventing or improving inflammatory diseases containing the anti-inflammatory composition.
또한, 상기 항염용 조성물은 본 발명의 건강기능식품에 0.001~100 중량%로 하여 첨가될 수 있다. 본 발명의 건강기능식품은 정제, 캡슐제, 환제 또는 액제 등의 형태를 포함하며, 본 발명의 항염용 조성물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 드링크제, 육류, 소세지, 빵, 캔디류, 스넥류, 면류, 아이스크림, 유제품, 스프, 이온음료, 음료수, 알코올 음료, 껌, 차 및 비타민 복합제 등이 있다. Additionally, the anti-inflammatory composition may be added in an amount of 0.001 to 100% by weight to the health functional food of the present invention. The health functional food of the present invention includes the form of tablets, capsules, pills, or liquid, and foods to which the anti-inflammatory composition of the present invention can be added include, for example, various drinks, meat, sausages, bread, These include candy, snacks, noodles, ice cream, dairy products, soups, electrolyte beverages, beverages, alcoholic beverages, gum, tea, and vitamin complexes.
또 다른 양태에서 본 발명은 상기 항염용 조성물을 포함하는 화장료 조성물을 제공할 수 있다. 상기 화장료 조성물의 제형으로는 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 에센스, 로션, 에멀젼, 팩, 핸드크림, 풋크림, 립밤, 립스틱, 아이섀도우, 아이라이너, 아이브로우 펜슬, 블러셔, 하이라이터, 일반화장수, 스킨, 크림, 세럼, 미용비누, 유연화장수, 약용화장수, 전신세정제, 클렌징폼, 클렌징로션, 겔, 클렌징 오일, 클렌징 크림, 샴푸, 린스, 헤어트리트먼트, 헤어로션, 클렌징 티슈 및 클렌징 워터에서 선택되는 것을 제공할 수 있다. In another aspect, the present invention can provide a cosmetic composition containing the anti-inflammatory composition. The formulation of the cosmetic composition is It can be manufactured in any formulation commonly manufactured in the industry, including essence, lotion, emulsion, pack, hand cream, foot cream, lip balm, lipstick, eye shadow, eyeliner, eyebrow pencil, blusher, highlighter, general Toner, skin, cream, serum, beauty soap, softening lotion, medicated lotion, body cleanser, cleansing foam, cleansing lotion, gel, cleansing oil, cleansing cream, shampoo, conditioner, hair treatment, hair lotion, cleansing tissue and cleansing water. It is possible to provide a selection from .
본 발명의 화장료 조성물에는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 성분, 또는 통상의 화장료용 부형제가 추가로 포함될 수 있다. The cosmetic composition of the present invention may further include ingredients selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids, and seaweed extract, or excipients for conventional cosmetics.
본 발명은 매실 착즙액을 유효성분으로 함유하는 항염용 조성물에 관한 것에 관한 것으로서, 상기 사료 조성물은 벽오동 추출물, 아까시 추출물, 머위 추출물, 계피 추출물 및 아스파라거스 추출물이 더 추가됨으로써 인체에 무해하면서도 각종 염증 증상을 억제하는 효능이 우수하여, 대장염, 관절염, 간염, 방광염, 신장염, 피부염 등과 같은 다양한 염증질환의 치료제, 증상 개선용 식품, 화장료 등으로 사용가능하다. The present invention relates to an anti-inflammatory composition containing plum juice as an active ingredient. The feed composition is harmless to the human body and causes various inflammatory symptoms by further adding paulownia extract, acacia extract, butterbur extract, cinnamon extract, and asparagus extract. It has excellent efficacy in suppressing , and can be used as a treatment for various inflammatory diseases such as colitis, arthritis, hepatitis, cystitis, nephritis, dermatitis, etc., food for improving symptoms, and cosmetics.
이하 본 발명의 바람직한 실시예를 상세히 설명하기로 한다. 그러나, 본 발명은 여기서 설명되는 실시예에 한정되지 않고 다른 형태로 구체화될 수도 있다. 오히려, 여기서 소개되는 내용이 철저하고 완전해지도록, 당업자에게 본 발명의 사상을 충분히 전달하기 위해 제공하는 것이다. Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. Rather, it is provided to ensure that the content introduced here is thorough and complete, and to sufficiently convey the spirit of the present invention to those skilled in the art.
<실시예 1 내지 6. 항염용 조성물의 제조><Examples 1 to 6. Preparation of anti-inflammatory composition>
청매실을 생것 상태로 분쇄하여 착즙하고 90℃에서 1시간 동안 1차 가열하였다. 가열한 액상을 4℃에서 8000rpm으로 30분간 원심분리하고 거름종이로 필터하여 다시 1차 조건과 동일하게 2차 가열하였다. 이 후 0.2μm 필터로 필터하여 매실 착즙액을 얻었다. Fresh green plums were crushed, squeezed, and first heated at 90°C for 1 hour. The heated liquid was centrifuged at 4°C at 8000 rpm for 30 minutes, filtered with filter paper, and heated a second time under the same conditions as the first. Afterwards, it was filtered with a 0.2μm filter to obtain plum juice.
벽오동은 가지, 열매 및 잎을 동일 중량으로 혼합하여 시료를 준비하고, 아까시(아카시아)는 가지와 줄기의 목질부, 계피로는 육계나무의 껍질을 준비하였다. 벽오동, 아까시, 머위(열매), 계피, 아스파라거스는 생것 상태로 준비하였다. 벽오동부터 계피까지 각 원료는 1kg 당 10kg의 물을 첨가하여 80℃에서 5시간 동안 가열 추출하고 건더기를 제거하여 얻은 액상을 식혀서 그대로 사용하였다. For paulownia, samples were prepared by mixing branches, fruits, and leaves in equal weight, for acacia, the xylem of branches and stems, and for cinnamon, the bark of the cinnamon tree was prepared. Byeok paulownia, acacia, butterbur (fruit), cinnamon, and asparagus were prepared in a raw state. Each raw material, from wall paulownia to cinnamon, was heated and extracted at 80°C for 5 hours by adding 10 kg of water per 1 kg, and the liquid obtained by removing the dry matter was cooled and used as is.
청매실과 설탕을 동일 중량으로 혼합한 혼합물을 3개월 동안 25℃의 서늘하고 그늘진 실온에 그대로 둔 후 매실로부터 즙이 충분히 추출되면, 건더기를 제거하고 액상을 수거하여 매실 당 추출물을 얻었다. A mixture of equal weights of green plums and sugar was left at a cool, shaded room temperature of 25°C for 3 months, and when the juice was sufficiently extracted from the plums, the dry matter was removed and the liquid was collected to obtain a plum sugar extract.
다음으로는 상기 매실 착즙액 100g 기준 하기 표 1과 같이 혼합하여 항염용 조성물을 제조하였다. Next, an anti-inflammatory composition was prepared by mixing 100 g of the plum juice as shown in Table 1 below.
착즙액
(g)plum
juice
(g)
추출물
(g)Byeokgodong
extract
(g)
(g)Acacia extract
(g)
추출물
(g)coltsfoot
extract
(g)
추출물
(g)cinnamon
extract
(g)
라거스
추출물
(g) Aspa
lagus
extract
(g)
(g)Plum Sugar Extract
(g)
(g)sum
(g)
<비교예 1 내지 6. 비교조건 항염용 조성물의 제조><Comparative Examples 1 to 6. Preparation of anti-inflammatory composition under comparative conditions>
표 2의 조건으로 비교용 항염용 조성물을 제조하였다. 각 원료와 제조방법은 실시예 1에서와 동일하게 하였다. A comparative anti-inflammatory composition was prepared under the conditions in Table 2. Each raw material and manufacturing method were the same as in Example 1.
착즙액
(g)plum
Juice
(g)
(g)Paulownia Extract
(g)
(g)Acacia extract
(g)
(g)butterbur extract
(g)
(g)cinnamon extract
(g)
라거스
추출물
(g) Aspa
lagus
extract
(g)
(g)Plum Sugar Extract
(g)
(g)sum
(g)
<실험예 1. 세포 독성 확인> <Experimental Example 1. Confirmation of cytotoxicity>
96-웰 플레이트 (1.5 x 103 세포/웰)에 접종된 Raw264.7 세포에 농도별 각 항염용 조성물을 처리하였다. 24 시간 배양 후 WST-8 시약 (Dojindo)을 37 ℃에서 1 시간 동안 배지에 첨가하였다. 마이크로 플레이트 리더 (BioTek)를 사용하여 450nm에서 흡광도를 측정하였다. 이후 24시간 마다 흡광도를 측정하여 세포 생존율을 확인하였다. Raw264.7 cells inoculated in a 96-well plate (1.5 x 10 3 cells/well) were treated with each anti-inflammatory composition at different concentrations. After 24 hours of incubation, WST-8 reagent (Dojindo) was added to the medium for 1 hour at 37°C. Absorbance was measured at 450 nm using a microplate reader (BioTek). Afterwards, absorbance was measured every 24 hours to confirm cell viability.
각 시료에 대한 세포생존율은 대조군(시료 무처리군)의 세포 상태를 100%로 할 때의 값을 환산하여 그 생존율을 아래의 표 3에 나타내었다. The cell survival rate for each sample was converted to the value assuming the cell state of the control group (untreated group) was 100%, and the survival rate is shown in Table 3 below.
표 3을 참고하면, 본 발명에서 제조한 조성물은 모두 세포독성은 없는 것으로 확인된다. Referring to Table 3, it is confirmed that all compositions prepared in the present invention are not cytotoxic.
<실험예 2. 항염 효능 확인> <Experimental Example 2. Confirmation of anti-inflammatory efficacy>
RAW 264.7 세포를 2×106 cells/dish density로 60mm 플레이트(plate)에 분주하여 24시간 동안 플레이트에 부착시켰다. 염증반응을 유발하기 위해 1㎍/㎖ 농도의 LPS(lipopolysaccharide)와 각 항염용 조성물을 함유한 새로운 배지를 처리하여 24시간 배양하였다.RAW 264.7 cells were distributed on a 60mm plate at a density of 2×10 6 cells/dish and allowed to attach to the plate for 24 hours. To induce an inflammatory response, the cells were treated with new medium containing lipopolysaccharide (LPS) at a concentration of 1 μg/ml and each anti-inflammatory composition and cultured for 24 hours.
RAW 264.7 세포에서 생성되어 배양액에 존재하는 NO 수준을 그리스(Griess) 반응을 기본으로 하는 NO 디텍션키트(detection kit, intron사의 21021)를 사용하여 측정하였다. NO가 존재한다고 추정되는 배양액을 96 웰-플레이트(well plate)에 100㎕씩 분주한 후 N1 버퍼(sulfanilamide) 50㎕를 넣어 10분간 실온에서 반응시킨다. 이어서 N2 버퍼(naphthylethylenediamine) 50㎕를 넣고 10분간 실온에서 반응시킨 후 540nm에서 흡광도 측정하였으며, 각 NO 생성량은 아질산염 기준(nitrite standard)를 이용하여 얻은 표준검량곡선을 이용하여 산출하였다. The level of NO produced in RAW 264.7 cells and present in the culture medium was measured using a NO detection kit (21021 from Intron) based on the Griess reaction. Dispense 100 μl of the culture medium estimated to contain NO into a 96 well plate, add 50 μl of N1 buffer (sulfanilamide), and react at room temperature for 10 minutes. Next, 50 ㎕ of N2 buffer (naphthylethylenediamine) was added and reacted at room temperature for 10 minutes, and the absorbance was measured at 540 nm. The amount of NO produced was calculated using a standard calibration curve obtained using a nitrite standard.
양성대조군(Positive control)으로는 LPS를 사용하였다. LPS was used as a positive control.
시료 0.5w%
처리군LPS+
Sample 0.5w%
Treatment group
시료 1w%
처리군LPS+
Sample 1w%
Treatment group
시료 2w%
처리군LPS+
Sample 2w%
Treatment group
(시료 및 LPS 무처리군)control group
(Sample and LPS untreated group)
단독
처리군LPS
single
Treatment group
표 4에서 볼 수 있는 바와 같이, 실시예 1 내지 6의 항염용 조성물의 NO 억제 활성이 비교예 1 내지 6의 조성물에 비교하여 매우 좋은 것을 확인할 수 있다.As can be seen in Table 4, it can be seen that the NO suppression activity of the anti-inflammatory compositions of Examples 1 to 6 is very good compared to the compositions of Comparative Examples 1 to 6.
Claims (9)
상기 조성물에는 벽오동 추출물, 아까시 추출물, 머위 추출물, 계피 추출물 및 아스파라거스 추출물이 함유된 것을 특징으로 하는 항염용 조성물.According to paragraph 1,
An anti-inflammatory composition comprising paulownia extract, acacia extract, butterbur extract, cinnamon extract, and asparagus extract.
상기 조성물에는 매실 당 추출물이 함유된 것을 특징으로 하는 항염용 조성물.According to paragraph 2,
An anti-inflammatory composition, characterized in that the composition contains plum sugar extract.
매실 착즙액은 생매실을 분쇄하고 압착 후 수득한 액상을 가열하여 얻은 것을 특징으로 하는 항염용 조성물.According to paragraph 1,
Plum juice is an anti-inflammatory composition obtained by crushing raw plums, pressing them, and heating the resulting liquid.
상기 염증 질환은 아토피 피부염, 부종, 피부염, 알레르기, 천식, 결막염, 치주염, 비염, 중이염, 인후염, 편도염, 폐렴, 위궤양, 위염, 크론병, 대장염, 치질, 통풍, 간직성 척추염, 류마티스 열루푸스, 섬유근통(fibromyalgia), 건선관절염, 골관절염, 류마티스관절염, 견관절주위염, 건염, 건초염, 근육염, 간염, 방광염, 신장염, 쇼그렌 증후군(sjogren's syndrome) 및 다발성 경화증으로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 염증 질환의 예방 또는 치료용 약학 조성물.According to clause 5,
The above inflammatory diseases include atopic dermatitis, edema, dermatitis, allergy, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, pharyngitis, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, mesenteric spondylitis, rheumatic fever, Inflammatory diseases characterized by being selected from the group consisting of fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendinitis, tenosynovitis, myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome, and multiple sclerosis. Pharmaceutical composition for prevention or treatment.
상기 염증 질환은 아토피 피부염, 부종, 피부염, 알레르기, 천식, 결막염, 치주염, 비염, 중이염, 인후염, 편도염, 폐렴, 위궤양, 위염, 크론병, 대장염, 치질, 통풍, 간직성 척추염, 류마티스 열루푸스, 섬유근통(fibromyalgia), 건선관절염, 골관절염, 류마티스관절염, 견관절주위염, 건염, 건초염, 근육염, 간염, 방광염, 신장염, 쇼그렌 증후군(sjogren's syndrome) 및 다발성 경화증으로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 염증 질환의 예방 또는 또는 개선용 건강기능식품.In clause 7,
The above inflammatory diseases include atopic dermatitis, edema, dermatitis, allergy, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, pharyngitis, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, mesenteric spondylitis, rheumatic fever, Inflammatory diseases characterized by being selected from the group consisting of fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendinitis, tenosynovitis, myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome, and multiple sclerosis. Health functional food for prevention or improvement.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220100612A KR20240023267A (en) | 2022-08-11 | 2022-08-11 | Anti-inflammatory composition containing plum juice as an active ingredient |
| PCT/KR2023/008219 WO2024034827A2 (en) | 2022-08-11 | 2023-06-14 | Anti-inflammatory composition containing plum juice as active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220100612A KR20240023267A (en) | 2022-08-11 | 2022-08-11 | Anti-inflammatory composition containing plum juice as an active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240023267A true KR20240023267A (en) | 2024-02-21 |
Family
ID=89851896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220100612A KR20240023267A (en) | 2022-08-11 | 2022-08-11 | Anti-inflammatory composition containing plum juice as an active ingredient |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20240023267A (en) |
| WO (1) | WO2024034827A2 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050117975A (en) | 2004-06-12 | 2005-12-15 | 김진수 | Natural antioxidant composition with an extract of chinese parasol tree and manufacturing method thereof |
| KR101384410B1 (en) | 2008-05-05 | 2014-04-10 | 얀타이 뉴 에라 헬스 인더스트리 씨오., 엘티디 | The use of the extract of prunus mume for preparation of compositions |
| KR101836679B1 (en) | 2015-08-19 | 2018-04-20 | 중앙대학교 산학협력단 | Pharmaceutical composition for preventing or treating IL-1β related diseases comprising Robinia pseudoacacia extract |
| KR102141623B1 (en) | 2018-12-20 | 2020-08-05 | 동의대학교 산학협력단 | Composition for prevention or treatment of dental disease comprising an extract of cinnamon |
-
2022
- 2022-08-11 KR KR1020220100612A patent/KR20240023267A/en unknown
-
2023
- 2023-06-14 WO PCT/KR2023/008219 patent/WO2024034827A2/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050117975A (en) | 2004-06-12 | 2005-12-15 | 김진수 | Natural antioxidant composition with an extract of chinese parasol tree and manufacturing method thereof |
| KR101384410B1 (en) | 2008-05-05 | 2014-04-10 | 얀타이 뉴 에라 헬스 인더스트리 씨오., 엘티디 | The use of the extract of prunus mume for preparation of compositions |
| KR101836679B1 (en) | 2015-08-19 | 2018-04-20 | 중앙대학교 산학협력단 | Pharmaceutical composition for preventing or treating IL-1β related diseases comprising Robinia pseudoacacia extract |
| KR102141623B1 (en) | 2018-12-20 | 2020-08-05 | 동의대학교 산학협력단 | Composition for prevention or treatment of dental disease comprising an extract of cinnamon |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024034827A2 (en) | 2024-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20110130546A (en) | A composition comprising the extract of physalis alkekengi var. francheti (masters) hort as an active ingredient for preventing and treating inflammatory disease | |
| KR102182724B1 (en) | Antiinflammatory composition comprising Locusta migratoria extract | |
| KR101348729B1 (en) | Eudesman compounds, thereof and compositions for containing the same as an active ingredient | |
| KR101794006B1 (en) | Anti inflammatory comprising plant extract | |
| KR101944014B1 (en) | Antiobesitic composition comprising extract of Rhododendron mucronulatum | |
| KR20160127188A (en) | An anti-inflammatory Cosmetic Composition comprising the extracts of Allium sativum L. stems | |
| KR101692889B1 (en) | Composition comprising an extract or a fraction of Daphne kamtschatica for preventing or treating inflammatory diseases | |
| KR20210117470A (en) | Composition for antioxidant or antiinflammation containing extract of citrus grandis osbeck | |
| KR101487065B1 (en) | A pharmaceutical composition for prevention or treatment of inflammatory disease comprising Myagropsis myagroides extracts or fraction thereof as an effective ingredient | |
| KR101604347B1 (en) | Pharmaceutical composition comprising an extract or a fraction of Pistacia weinmannifolia J. Poiss. Ex Franch for preventing or treating inflammatory-related diseases | |
| KR20240023267A (en) | Anti-inflammatory composition containing plum juice as an active ingredient | |
| KR102368892B1 (en) | A composition for anti-inflammatory comprising extracts of single leaf cremastra and sigesbeckia glabrescens makino | |
| KR101207239B1 (en) | A composition for the prevention and treatment of inflammatory disease comprising the fractions of Asparagus cochinchinensis as an active ingredient | |
| KR102076176B1 (en) | Composition for Anti-inflammation Using an Ginsenoside compound K and an Extract of Lonicera japonica | |
| KR102092872B1 (en) | Composition for anti-inflammation comprising Geumgangsong subcritical water extract as effective component | |
| KR102010691B1 (en) | Composition for Anti-inflammation Using Pratol | |
| KR102058022B1 (en) | Composition for antioxidant and anti-inflammatory comprising fraction of Ledum palustre L. extract as effective component | |
| KR101739425B1 (en) | Composition for preventing or improving inflammatory disorders comprising fraction of Oenanthe javanica ethanol extract as effective component | |
| KR102636204B1 (en) | Antiinflammatory or antiallergic composition comprising extract of Salvia chanryoenica | |
| KR102575617B1 (en) | Composition comprising extract of Sageretia thea for immune-enhancement | |
| KR20190132032A (en) | Composition for Anti-inflammation Using Extract of Salix sp. Plant | |
| KR102471026B1 (en) | Cosmetic composition containing Cyperus spp. extract for antiinflammation or skin whitening | |
| KR102213459B1 (en) | Anti-atopic composition comprising extract of pepper seed meal as effective component | |
| KR102040527B1 (en) | Composition for Anti-inflammation Using Rhamnocitrin | |
| KR20100066076A (en) | An anti-inflammatory composition for the prevention and treatment of edema or a variety of inflammations containing koelreuteria paniculata extract or fraction thereof as an active ingredient |